| Filed On | Filing |
|---|---|
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition
Princeton, N.J., November 12, 2026 (GLOBE NEWSWIRE) — Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage biopharma company advancing GTx-104, a novel, injectable formulation of nimodipine that has c... |
| 18 Sep 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On September 17, 2026, Grace Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Meeting”). Proxies for the Meeting were solicited pursuant to Section 14(a) of the Securities Exchange Act of 1934, as amended,... |
| 13 Aug 2026 |
8-K: Results of Operations and Financial Condition
Princeton, NJ, August 13, 2026 (GLOBE NEWSWIRE)—Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine... |
| 06 Aug 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of August 4, 2026, by and among Grace Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (... |
| 28 Jul 2026 |
8-K: Other Events
Summary 2 Forward Looking Statements Statements in this presentation that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of... |
| 18 Jun 2026 |
8-K: Other Events
Summary 2 Forward Looking Statements Statements in this presentation that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of... |
| 18 Jun 2026 |
8-K: Results of Operations and Financial Condition
Type A Meeting Scheduled with FDA to Potentially Clarify Path to GTx-104 NDA Resubmission |
| 05 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
This Consulting Agreement (“Agreement”) is effective as of June 5, 2026 (the “Effective Date”) by and between Grace Therapeutics, Inc., a Delaware corporation, with a business address of 103 Carnegie Center, Suite 300, Princeton, NJ 0854... |
| 27 Apr 2026 |
8-K: Other Events
Summary 2 Forward Looking Statements Statements in this presentation that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of... |
| 23 Apr 2026 |
8-K: Other Events
FDA Issued Complete Response Letter Citing Outstanding Items Related to Chemistry, Manufacturing, and Controls and Non-Clinical Information |
| 12 Feb 2026 |
8-K: Results of Operations and Financial Condition
FDA Established April 23, 2026 as PDUFA Target Date for Review of Submission Seeking Approval for GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) |
| 12 Jan 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
This letter serves to modify and amend the Letter Agreement (“Letter Agreement”) dated as of November 12, 2025, between you and Grace Therapeutics, Inc. (“Company”) containing the terms and conditions of your employment as Vice President... |
| 13 Nov 2025 |
8-K: Results of Operations and Financial Condition; Other Events
Announced U.S. Food and Drug Administration (FDA) Acceptance for Review |
| 23 Oct 2025 |
8-K: Other Events
Grace Therapeutics Secures Approximately $4.0 Million through Common Warrant Exercises Following Acceptance of New Drug Application for GTx-104 for formal FDA Review |
| 18 Sep 2025 |
8-K: Other Events
Grant of First Method of Use Patent Adds New Pillar to Grace’s Multi-layered Intellectual Property and Potential Market Exclusivity Protection |
| 12 Sep 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On September 12, 2025, Grace Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Meeting”). Proxies for the Meeting were solicited pursuant to Section 14(a) of the Securities Exchange Act of 1934, as amended,... |
| 27 Aug 2025 |
8-K: Other Events
FDA Establishes April 23, 2026 as PDUFA Target Date for Review of Submission Seeking Approval for GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) |
| 12 Aug 2025 |
8-K: Results of Operations and Financial Condition
Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for GTx-104 Seeking Approval of GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) |
| 25 Jun 2025 |
8-K: Other Events
Submission Seeks Approval of GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) |
| 23 Jun 2025 |
8-K: Results of Operations and Financial Condition
Held Type C meeting with FDA on Planned New Drug Application (NDA) Submission, Including Clinical, Non-clinical, and Chemistry, Manufacturing, and Control (CMC) Requirements |
Loading...